Malignant astrocytomas constitute a spectrum of clinicopathological entities, from low- to high-grade malignancies. The World Health Organization (WHO) classifies these tumors into four grades according to their histological and anaplastic characteristics. Glioblastoma (GBM) (WHO grade 4) is the most common primary brain tumor in adults and also the most malignant (1). It is distinguished pathologically from lower-grade astrocytomas (grades 2 and 3) by the marked presence of necrosis and/or microvascular hyperplasia (2). GBM is characterized by rapid cell proliferation and marked propensity to invade and damage the surrounding normal brain tissue rendering the complete surgical resection impossible. Despite available treatments, including surgical resection, chemotherapy and radiotherapy, the vast majority of patients exhibit a poor median survival of 15 months following diagnosis (3). Therefore, the development of novel therapeutic approaches to treat GBM remains of critical importance (4).

Increasing evidence has supported the hypothesis that a rare subpopulation of cancer cells sharing stem-cell characteristics within GBM has a potent capacity for tumor propagation (5). These cells are termed tumor precursor cells (TPCs); they demonstrate greater tumorigenic potential compared with matched non-stem tumor cells (6,7). A2B5 antigen has been recognized as a marker for neural progenitor cells, and explants from A2B5+ tumor cells display typical progenitor morphology that clearly indicates their immature state (8). Nunes and colleagues showed that the majority of A2B5+ multipotential progenitor cells differentiate into oligodendrocytes and a minority of these cells differentiate to neurons (9). A2B5+ cells, but not A2B5− cells isolated from GBM, have neural stem cell-like properties (10). Glioma TPCs have marked self-renewal properties and
may generate a number of heterogeneous lineages of cancer cells, which eventually constitute a tumor (11). Therefore, TPCs have been proposed as targets for new therapeutic strategies for the treatment of GBM (12).

Messenger RNA profiling has identified a cohort of genes that distinguish A2B5+ glioma TPCs from A2B5+ normal glial progenitor cells, including the F2R gene that encodes protease-activated receptor 1 (PAR1) (13). PAR1 belongs to a family of four distinct G-protein coupled receptors, which share a unique mechanism of activation that relies on the proteolytic cleavage of their N-terminal ectodomains by specific proteases, including blood coagulation factors. Therefore, PAR1 has long been regarded as a “thrombin receptor”, although it is processed by other proteases. Cleavage of PARs unmasks a new N-terminus, which serves as a tethered ligand that binds to the second extracellular domain of the protein, resulting in a variety of cellular responses that exert important roles in hemostasis, thrombosis and vascular biology (14,15). In addition to their roles in physiological processes, PARs contribute to numerous pathological processes, including tumor biology (16,17). In particular, PAR1 promotes transformation of NIH3T3 cells leading to potent focus-forming activity and loss of anchorage- and serum-dependent growth (18). Several studies have demonstrated a correlation between PAR1 expression/activation and a number of pro-tumor responses, including primary growth, evasion of apoptosis, invasion, metastasis, angiogenesis and epithelial-mesenchymal transition (19-23). A number of studies also demonstrated that PAR1 is overexpressed in GBM (24-26). Indeed, upregulation of PAR1 in gliomas correlates with histological malignancy grade (24,25) and has been shown to be a strong prognostic marker for decreased overall survival (25).

Nearly all GBMs exhibit microscopic intravascular thrombosis within tissue specimens and this event has been documented as an additional distinguishing pathological feature of GBM relative to lower-grade astrocytomas (27). The prothrombotic phenotype of GBM has been largely attributed to the potent procoagulant properties of tumor cells. These properties arise from the increased expression of the clotting initiator protein, tissue factor (TF). TF is highly expressed by GBM cell lines (28-30) and its expression levels in human glioma samples correlate with the grade of malignancy in astrocytomas (31,32). Furthermore, TF expression may impact early stages of gliomagenesis by influencing the dormancy of indolent tumor cells. It is believed that tumor-derived TF allows the formation of a permissive microenvironment containing angiogenic and inflammatory cells. The microenvironment orchestrated by TF expression may drive permanent changes in the phenotype, gene expression profile, DNA copy number, and DNA methylation state of the tumor cells that escape from dormancy (33). In accordance with this hypothesis, some studies have demonstrated an ability of TF inhibitors to decrease GBM growth in rodent models. Ixolaris, a tick-derived protease inhibitor, inhibited the in-vivo tumorigenic potential of U87-MG cells in nude mice. The antitumor effect of ixolaris was associated with downregulation of VEGF and reduced tumor vascularization (34), possibly mediated by decreased thrombin generation in the tumor microenvironment (thus affecting PAR1 activation) and/or by decreased PAR2 signaling in tumor cells (35). In the same line, monoclonal antibodies against TF, including CNTO 859 (which blocks TF-mediated thrombin generation) and 10H10 (which blocks TF-PAR2 signaling), reduce tumor cell invasion in vitro (36) as well as tumor growth in vivo in SCID mice (37).

Some studies previously suggested that the coagulopathy in cancer and the expression of hemostasis-related genes are affected by oncogenic alterations (38,39). For example, overexpression and activating mutations of the epidermal growth factor receptor (EGFR) and loss of tumor suppressor PTEN function drive the upregulation of TF in GBM cells (40). EGFR is a transmembrane tyrosine kinase receptor that plays a central role in cell biology. Ligand binding to the extracellular domain of the receptor leads to functionally active dimers, thereby activating the tyrosine kinase domain. Then autophosphorylation of the receptor occurs on multiple tyrosine residues. This leads to recruitment of a range of adaptor proteins and activates a series of intracellular signaling cascades, such as PI3K-Akt and MAPK pathways, that affect gene transcription, resulting in cancer cell proliferation, reduced apoptosis, invasion and angiogenesis (41). The EGFR gene is amplified in 40% to 50% of GBMs and this event is often accompanied by genetic alterations (42). The most common mutant, EGFRvIII, is formed following the deletion of exons 2 to 7, resulting in a constitutively active receptor that lacks a functional ligand-binding domain (43).

Recent large-scale profiling studies of the genome, epigenome and transcriptome showed the existence of four different subtypes of GBM: proneural, neural, classical and mesenchymal. These subtypes are defined by distinct molecular signatures, as exemplified by the
PAR1 and elicit PAR1 signaling in a thrombin-independent manner (50,51). In gliomas, the upregulation of MMP-1 correlates with progression of histological malignancy grade and poor clinical outcome (25). Interestingly, it has been described that EGFR signaling also contributes to MMP-1 protein upregulation in GBM cells in vitro (52). Expression of PAR1 on vascular endothelium is well documented (15,51,53). The finding of PAR1 activation by MMP-1 suggests that this interaction may also contribute to tumor-host communication in the vascular compartment. Indeed, tumor-derived MMP-1 may induce a prothrombotic, proinflammatory, and adhesive state in endothelial cells expressing functional PAR1 (53). Thus, tumor-endothelial interactions may represent a crucial step in tissue colonization by tumor cells moving through the vascular compartment. Additionally, endothelial cell activation can cause dissociation of cell-cell junctions between endothelial cells as well as cytoskeleton contraction, leading to endothelial barrier disruption (15). Endothelial barrier disruption causes extravasation of plasma carrying coagulation factors (FVII, FX and prothrombin) which in the presence of tumor-derived TF are converted into active proteases, able to cleave PARs in tumor cells (17). Figure 1 summarizes the interactions between EGFR and the TF-PAR1 pathway in glioma TPCs, highlighting possible targets for the treatment of GBM.

Since the 1990s, various pharmaceutical companies have dedicated great effort to searching for potent and selective PAR1 antagonists, particularly in the context of thrombosis and atherosclerosis (51,54-56). Based on the roles of PAR1 in tumor progression, therapeutic strategies towards the inhibition of PAR1 have also been considered. Auvergne and colleagues showed that commercially available PAR1 antagonists, including SCH 530348 (vorapaxar), reduce the in-vitro aggressive properties of glioma TPCs (47). Vorapaxar is approved by the U.S. Food and Drug Administration for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction and peripheral artery disease, without a previous stroke or transient ischemic attack (56). Moreover, vorapaxar has been tested in two important clinical trials. Although there were conflicting results concerning the overall advantage of vorapaxar in relation to other cardiovascular drugs, both clinical trials demonstrated increased bleeding risk, including intracranial hemorrhage (56,57). These trials also revealed a number of diplopia (double vision) cases, thus defining an additional relevant side-effect (58). Although the use of vorapaxar may be limited due to its high potential for causing bleeding, it
is necessary to investigate efficacy and safety of vorapaxar in the treatment of GBM, since the survival of such patients is very short.

Another innovative strategy for the inhibition of PARs involves using cell-penetrating intracellular antagonists termed pepducins. These compounds are lipopeptides that target the cytoplasmic surface of their cognate receptor thus antagonizing PAR activity in a way that is distinct from classical PAR antagonists (51). PAR1 pepducin P1pal-7 blocked MMP-1-induced PAR1 activation of the Akt survival pathway in breast-cancer cells, resulting in apoptosis in tumor xenografts and inhibition of metastasis to the lungs by up to 88% (59). In principle, it is possible to design pepducins that block PAR-mediated activation of one signaling pathway without affecting other therapeutically desirable signaling pathways. Thus, this class of PAR1 antagonists may have fewer side effects and prove safer. It remains to be determined whether the pepducin compounds will be useful in the clinical setting (51).

Taken together, PAR1 expression in TPCs, along with the establishment of a permissive microenvironment that prompts its activation, may play a major role in GBM progression. A cooperation between EGFR and PAR1 in gliomagenesis might also be considered. Future advances in the treatment of GBM might rely on more effective and better-tolerated therapies, among which PAR1-targeted agents are an attractive option.

**Acknowledgements**

The authors are grateful to Dr. Martha Sorenson (UFRJ) for the critical reading of the manuscript and to Dr. Rômulo Galvani (romulo.galvani@ufrj.br) for graphic design of the model of glioma TPC.

**Footnote**

*Provenance:* This is a Guest Perspective commissioned by the Section Editor Ning Huang (Department of Neurosurgery, the Second Affiliated Hospital of Chongqing
Medical University, Chongqing, China).

Conflicts of Interest: The authors have no conflicts of interest to declare.


References


41. Boire A, Covic L, Agarwal A, et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and...